Ritonavir diminishes methadone plasma concentrations, an effect attributed to CYP3A induction, but the actual mechanisms are unknown. We determined short-term (2-day) and steady-state (2-week) ritonavir effects on intestinal and hepatic CYP3A4/5 (probed with intravenous (IV) and oral alfentanil (ALF) and with miosis) and P-glycoprotein (P-gp) (fexofenadine), and on methadone pharmacokinetics and pharmacodynamics in healthy volunteers. Acute ritonavir increased the area under the concentration-time curve (AUC) 0-∞ /dose ratio (ritonavir/control) for oral ALF 25-fold. Steady-state ritonavir increased the AUC 0-∞ /dose ratio for IV and oral ALF 4-and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%). Acute ritonavir inhibits first-pass CYP3A >96%. Chronic ritonavir inhibits hepatic CYP3A (>70%) and first-pass CYP3A (>90%). Acute and steady-state ritonavir increased the fexofenadine AUC 0-∞ 2.8-and 1.4-fold, respectively, suggesting P-gp inhibition. Steady-state compared with acute ritonavir caused mild apparent induction of P-gp and hepatic CYP3A, but net inhibition still predominated. Ritonavir inhibited both intestinal and hepatic CYP3A and drug transport. ALF miosis noninvasively determined CYP3A inhibition by ritonavir.
The human immunodeficiency virus (HIV) protease inhibitor ritonavir is the most potent and efficacious clinical inhibitor of CYP3A, and it is now a standard component of highly active retroviral therapy, included in the therapy for boosting the systemic exposure of other antiretrovirals through inhibition of firstpass and hepatic CYP3A activity. 1 Ritonavir, both alone and in combination with other antiretrovirals, causes well-documented decreases in both S-and R-methadone (the active enantiomer) plasma concentrations and area under the concentration-time curve (AUC), increases methadone clearance, and variably causes methadone withdrawal symptoms. 2 Ritonavir and other protease inhibitor effects on methadone disposition and clearance have been attributed to CYP3A induction in some reports. [3] [4] [5] [6] [7] Nonetheless, the apparent paradox of ritonavir induction of methadone clearance, despite profound inhibition of CYP3A activity, has never been addressed. Methadone is also a substrate for the efflux transporter P-glycoprotein (P-gp) in vitro, and in the intestine and brain of animals in vivo, where it influences methadone absorption, brain access, pharmacodynamics, and analgesic effects. [8] [9] [10] [11] The role of P-gp in determining human methadone intestinal absorption and bioavailability is unknown. Ritonavir has been reported to inhibit renal tubular and hepatic P-gp in humans in vivo [12] [13] [14] and to induce P-gp in a human intestinal cell line and in rats in vivo, 15, 16 but the role of P-gp in ritonavir alterations in methadone disposition is unknown. Indeed, the mechanism(s) of ritonavir alteration of methadone pharmacokinetics and clinical effects remains fundamentally unidentified.
The duration of ritonavir administration may affect the degree of CYP3A inhibition. Short-term ritonavir causes inhibition. Longer-term administration has been reported to cause apparent induction, or relative induction compared with acute administration but with net inhibition predominating. [17] [18] [19] Whether ritonavir interactions occur secondary to modulation of hepatic or intestinal CYP3A is not well understood. 20 The purpose of this clinical investigation was to determine (i) mechanism(s) of acute and steady-state ritonavir alterations in methadone disposition and clinical effect, including the roles of CYP3A4/5-and/or P-gp-mediated methadone bioavailability, first-pass metabolism, and systemic clearance; (ii) the influence of ritonavir on methadone pharmacodynamics; (iii) acute and steady-state ritonavir effects on hepatic CYP3A4/5, first-pass CYP3A4/5, and intestinal P-gp activities, using validated in vivo probes; and (iv) the ability of a noninvasive in vivo CYP3A4/5 probe to detect ritonavir drug interactions and predict methadone disposition.
A comprehensive crossover investigation was conducted in healthy volunteers (Figure 1 ). An accompanying article in this issue describes ritonavir effects on methadone pharmacokinetics and pharmacodynamics. 21 This article reports ritonavir effects on CYP3A4/5 and P-gp activities. The P-gp substrate fexofenadine was used as the in vivo P-gp probe. 22, 23 Hepatic and firstpass CYP3A4/5 activities were evaluated using intravenous (IV) and oral alfentanil (ALF) as the in vivo probe. 24, 25 ALF is metabolized similarly by CYP3A4 and CYP3A5, while CYP3A7 has significantly less activity, 26, 27 and CYP3A5 polymorphisms have no effect on IV or oral ALF clearances; 25 hence we consider ALF to be a nonselective CYP3A4/5 (henceforth collectively referred to as CYP3A) probe. Pupil diameter change (miosis) was used as a surrogate for ALF plasma concentrations to noninvasively estimate ALF clearance and hence CYP3A activity. 24, 25 
RESuLTS
The initial protocol design involved fexofenadine, IV ALF, oral ALF, and methadone on sequential days, with constant ALF doses (15 μg/kg IV and 43 μg/kg oral) in the control and ritonavir arms. Plasma samples were to be batched and analyzed at the conclusion of the investigation; however, pupil diameter results were available in real time. Figure 2 shows IV and oral ALF miosis for the control and ritonavir sessions. Prolonged ALF miosis was apparent during the ritonavir sessions, indicating markedly delayed ALF elimination. Carryover of ALF miosis into subsequent (methadone study) days confounded the methadone pupil data. Based on this subject's pupil data, the protocol was redesigned. The IV and oral ALF doses for the ritonavir sessions were reduced to 5 and 4.3 μg/kg, respectively, which allowed complete ALF elimination and prevented carryover to the next day's study session. Coincidentally, simultaneous assessments of first-pass CYP3A and P-gp activity with oral ALF and fexofenadine were validated, 28 so the oral ALF and fexofenadine sessions were combined and scheduled prior to the IV ALF session. The final protocol design is shown in Figure 1 . ALF data and methadone pupil data for the first subject were excluded from the final analysis.
Ritonavir caused profound inhibition of hepatic and first-pass CYP3A activity. Initially available data were from ALF miosis, Figure 2 Effect of acute ritonavir on first-pass and hepatic CYP3A activity, assessed with alfentanil (ALF) as a CYP3A probe. Miosis was used as a surrogate for ALF plasma concentrations. Results are shown as the measured dark-adapted pupil diameter (not baseline-subtracted) for the first study subject, who received (a) 15 μg/kg intravenous (IV) ALF and (b) 43 μg/kg oral ALF on sequential days, at the control and ritonavir sessions. Prolonged ALF miosis is apparent during ritonavir treatment, indicating markedly delayed ALF elimination (later verified by plasma analysis at the conclusion of the entire investigation). Carryover of ALF miosis into subsequent methadone study days confounded the methadone pupil data. Based on these pupil data, the protocol was redesigned, with IV and oral ALF dose reduction to 5 and 4.3 μg/kg, respectively, for ritonavir sessions. This enabled complete ALF elimination and eliminated carryover to the following day's study session. articles used as a surrogate for ALF plasma concentrations ( Figure 3 and Table 1 ). 24, 25 Both short-term low-dose and steady-state higherdose ritonavir prolonged and enhanced miosis. The short-term ritonavir increased maximum dose-adjusted miosis after oral ALF 8-fold. Longer-duration ritonavir increased maximum dose-adjusted IV ALF miosis 3-fold and maximum oral ALF miosis 7-fold. The dose-normalized area under the miosis-time curve (AUEC 0-∞ /dose) ratio (ritonavir/control) for oral ALF was increased 18-fold by acute ritonavir, and steady-state ritonavir increased the dose-normalized AUEC 0-∞ ratio for IV and oral ALF 3-and 7-fold. The effects of ritonavir on ALF plasma concentrations are shown in Figure 4 , and the pharmacokinetic parameters are provided in Table 2 . The dose-normalized AUC 0-∞ ratio (ritonavir/control) for oral ALF was increased 25-fold by acute ritonavir, and steady-state ritonavir increased the dose-normalized AUC 0-∞ ratio for IV and oral ALF 4-and 10-fold, respectively. These results indicate 72% inhibition of hepatic ALF clearance and CYP3A activity by steady-state ritonavir and 96 and 90% inhibition of first-pass ALF clearance and CYP3A activity by acute low-dose and steady-state higher-dose ritonavir, respectively. Steady-state ritonavir reduced mean hepatic ALF extraction from 0.26 to 0.07 and intestinal Subjects received 15 and 5 μg/kg intravenous (IV) alfentanil (ALF) at the control and ritonavir sessions, respectively, and 43 and 4.3 μg/kg oral ALF at the control and ritonavir sessions, respectively. One subject received 15 μg/kg IV ALF and 43 μg/ kg oral ALF at control and ritonavir sessions and was omitted from the analysis of ALF pharmacokinetics. Peak plasma concentration (C max ) and area under the concentration-time curve (AUC) are shown normalized to dose. All other variables are not dose adjusted. Results are the arithmetic mean ± SD (n = 11), except for the AUC 0-∞ / dose ratio (ritonavir/control), which is the geometric mean (90% confidence interval).
CL/F, oral clearance of ALF; CL IV , systemic clearance of IV ALF; E G , intestinal extraction; E H , hepatic extraction; F oral , bioavailability. a Significantly different from control (P < 0.05). b Significantly different from acute ritonavir (P < 0.05).
articles extraction from 0.51 to 0 and increased ALF bioavailability from 37 to 95%. Ritonavir had time-and dose-dependent effects on plasma fexofenadine concentrations ( Figure 5 ). Short-term low-dose ritonavir increased plasma concentrations C max (by 60%), and the AUC 0-∞ ratio (ritonavir/control) nearly 3-fold ( Table 3) . Steady-state higher-dose ritonavir had a diminished but still significant effect, increasing the AUC 0-∞ ratio 1.4-fold. Ritonavir had no effect on fexofenadine elimination half-life.
DISCuSSIon
One purpose of this investigation was to quantify the effects of short-term and steady-state ritonavir on hepatic and first-pass CYP3A activity. The major finding, as expected, was that ritonavir profoundly inhibited CYP3A. These results are consistent with the known effects of ritonavir on the pharmacokinetics of CYP3A substrates. Short-term ritonavir inhibited 96% of firstpass CYP3A, and steady-state ritonavir inhibited 72 and 90% of hepatic and first-pass activities, respectively, as assessed using ALF clearance as an in vivo probe. Steady-state ritonavir reduced ALF hepatic extraction from 0.26 to 0.07 and intestinal extraction from 0.51 to 0 and increased bioavailability from 37 to 95%. This is the first investigation to evaluate ritonavir effects on both hepatic and first-pass CYP3A and to show that ritonavir inhibits both intestinal and hepatic CYP3A activity.
CYP3A inhibition by steady-state higher-dose ritonavir was moderately diminished compared with short-term low-dose ritonavir. The dose-normalized ALF AUC 0-∞ ratios (ritonavir/ control) were 25 and 10 after short-term and steady-state ritonavir, respectively, and the mean ALF CL/F was 0.4 and 1.1 ml/ kg/min, respectively (vs. 12 ml/kg/min in controls). Similar long-term vs. short-term ritonavir effects on the oral clearance of other CYP3A substrates have been reported previously and attributed to longer-term CYP3A induction, although the site of induction (intestine vs. liver) was not identified, and the potential contribution of intestinal transporters could not be excluded. [17] [18] [19] 29 In the present investigation, since ALF intestinal extraction was zero after steady-state ritonavir, this cannot represent the site of effective CYP3A upregulation compared with short-term ritonavir. Thus it is more likely that the liver was the site of the mild functional upregulation of CYP3A. Direct comparison of short-term and steady-state ritonavir effects on hepatic and intestinal extraction coefficients was not possible, since this investigation did not evaluate acute ritonavir effects on IV ALF clearance. Overall, while mild CYP3A induction by steady-state ritonavir was apparent, it was clinically inconsequential given that profound inhibition of CYP3A activity by ritonavir was still dominant.
A second major purpose of this investigation was to assess the ability of the noninvasive in vivo probe, ALF miosis, to detect alterations in CYP3A activity and drug interactions. The results show that ALF miosis is an excellent predictor of ritonavir effects on both hepatic and first-pass CYP3A activity. From the immediately available miosis data, long before that of plasma ALF concentrations and formal clearance determinations, it was clear that ritonavir profoundly increased ALF AUEC 0-∞ and prolonged elimination of ALF effects. Changes in miosis were representative of alterations in CYP3A activity, with increases in AUEC 0-∞ ratios reflecting those in ALF plasma AUC. Moreover, the early availability of miosis data enabled a change in the protocol to prevent ALF carryover during ritonavir inhibition. Had a different CYP3A probe been used, with conventional batch plasma analysis after the conclusion of the entire investigation, such carryover would not have been known, and the results of the entire investigation would have been invalid. No other CYP3A probe offers such real-time assessment of CYP3A activity.
A third major purpose of this investigation was to determine the effect of ritonavir on gastrointestinal P-gp activity. The major finding was that ritonavir significantly inhibited P-gp activity. Short-term and steady-state ritonavir significantly increased apparent fexofenadine bioavailability without altering its elimination. Fexofenadine is a well-characterized substrate for human P-gp (ABCB1). 22, 30 The well-known P-gp inhibitors ketoconazole, 31 verapamil, 23, 32, 33 itraconazole, 34, 35 and erythromycin 36 increase plasma fexofenadine concentrations, and the P-gp inducers rifampin and St John's wort decrease plasma fexofenadine, 37,38 effects largely, although not exclusively, attributed to inhibition and upregulation of intestinal and/or hepatic P-gp. Hence fexofenadine has been used frequently as an in vivo probe to assess P-gp pharmacogenetics 
Figure 5
Effect of acute and steady-state ritonavir on intestinal transporter activity, assessed using fexofenadine as a transporter probe. Shown are plasma fexofenadine concentrations after 3 d and 2.5 weeks ritonavir. Each subject received 60 mg oral fexofenadine on each occasion. Each data point is the mean ± SD (n = 12). CL/F (ml/kg/min) 15.5 ± 5.6 5.4 ± 1.9 a 10.7 ± 6.5 a,b
Elimination t 1/2 (h) 10.6 ± 1.9 11.3 ± 2.5 10.4 ± 3.9
Results are the arithmetic mean ± SD (n = 12), except for the AUC 0-∞ ratio (ritonavir/ control), which is the geometric mean (90% confidence interval).
AUC, area under the concentration-time curve; C max , peak plasma concentration; CL/F, oral clearance of fexofenadine. a Significantly different from control (P < 0.05). b Significantly different from acute ritonavir (P < 0.05).
articles and drug interactions. 23, [31] [32] [33] 35, [37] [38] [39] [40] In the present investigation, short-term and steady-state ritonavir caused 2.8-and 1.4-fold increases, respectively, in fexofenadine AUC. The extent of ritonavir alterations of fexofenadine AUC and oral clearance is similar to that caused by other P-gp inhibitors, such as itraconazole and verapamil. It is well-established that CYP3A-mediated metabolism accounts for <1% of fexofenadine elimination, renal excretion accounts for <5-10%, and changes in renal fexofenadine excretion do not affect plasma concentrations because it is a minor route of elimination. 23, 33, 37 Hence it is unlikely that the observed effects of ritonavir on fexofenadine are attributable to changes in CYP3A or renal P-gp activity. Rather, they suggest ritonavir inhibition of intestinal and/or hepatic P-gp. P-gp is expressed on the luminal aspect of enterocytes and the canalicular aspect of hepatocytes. The site of action (intestinal vs. hepatic) of other P-gp inhibitors (verapamil, erythromycin, and ketoconazole) on first-pass fexofenadine extraction remains controversial; 23, 31, 32, 36 hence the present results do not discriminate the site of P-gp inhibition by ritonavir. Previous studies have also shown an effect of ritonavir on drug transport. Ritonavir (300 mg twice daily for 3 d) doubled the plasma AUC of IV digoxin, also a P-gp substrate, and decreased both nonrenal and renal clearances by 40-50%, which was ascribed to inhibition of renal tubular P-gp. 12 In contrast, 2 weeks of lowerdose (200 mg twice daily) ritonavir caused a 22% increase in oral digoxin AUC and 30% reduction in oral clearance, without altering digoxin renal clearance, effects that were attributed to inhibition of hepatic P-gp and reduced biliary fexofenadine excretion. 13 Single-dose ritonavir (100 mg) or lopinavir/ritonavir (400/100 mg) increased the fexofenadine plasma AUC two-and fourfold, respectively, without affecting fexofenadine elimination half-life, which was also attributed to hepatic P-gp inhibition. 14 Ritonavir has been shown to induce P-gp protein expression and transport activity in a human intestinal cell line and in rats in vivo. 15, 16 Fexofenadine is not exclusively transported by P-gp, and absorption has been suggested to involve active intestinal uptake transport as well as passive diffusion and active efflux. 31, 32, 36 Fexofenadine is a substrate for the uptake transporters OATP1A2 22 and OATP2B1 41 and for the liver-specific OATP1B1 and OATP1B3. 42, 43 A decrease fexofenadine bioavailability by citrus and apple juices was attributed to inhibition of intestinal OATP1A2-mediated uptake. 39 Increased fexofenadine bioavailability by verapamil and ketoconazole, which did not increase apparent intestinal permeability and absorption, 31, 32 was attributed instead to inhibition of hepatic first-pass extraction-specifically, decreased organic aniontransporting polypeptide (OATP)-mediated fexofenadine uptake across the sinusoidal membrane and/or inhibition of P-gp-mediated canalicular secretion. 31, 32 Thus a potential role for both intestinal P-gp efflux and OATP-mediated absorption in mediating fexofenadine bioavailability has been proposed, 31, 32 and some may consider fexofenadine an in vivo probe for OATP as well as for P-gp. Ritonavir has been shown to be an inhibitor of OATP-mediated fexofenadine transport, but such effects were small (13%). 22 Ritonavir inhibition of OATP in vivo would not explain the observed increase in fexofenadine bioavailability; hence P-gp inhibition remains the more likely explanation.
Ritonavir effects on fexofenadine AUC were biphasic. The 2-fold increase in AUC caused by short-term ritonavir (600 mg/d) was partially attenuated to a 1.4-fold increase after 2 weeks of ritonavir (800 mg/d). The phenomenon of shortterm inhibition of fexofenadine oral clearance, which abates over time despite continued inhibitor administration, has been previously described. Single dose verapamil or St John's wort caused an ~20-40% decrease in fexofenadine oral clearance, which slowly abated over the course of 2 (St John's wort) or 5 (verapamil) weeks. 23, 38 Long-term effects were attributed to P-gp induction, 38 supported by reported St John's wort induction of immunodetectable duodenal P-gp expression. 44 Similar effects of short-term (1 week) and longer-term (6 weeks) verapamil on the clearance of the P-gp substrate digoxin, were also reported. 45 Single-dose lopinavir/ritonavir increased the fexofenadine AUC fourfold, while steady-state lopinavir/ritonavir effects were attenuated to a nonsignificant threefold increase, attributed to mild steady-state P-gp induction (although net P-gp inhibition prevailed). 14 Ritonavir effects in the present investigation could be explained by acute P-gp inhibition, partially counteracted by long-term P-gp induction, albeit with net strong inhibition prevailing. Alternatively, these results could be explained by P-gp inhibition followed by concomitant OATP induction. Nevertheless, although ritonavir moderately induced P-gp mRNA expression, it had little or no effect on OATP1B1 or OATP1B3. 46 Ritonavir effects on human intestinal and hepatic P-gp and OATP expression in vivo have not been reported.
There are recognized potential limitations of this investigation. First, the ritonavir dose differs from that used in typical contemporary "boosted" antiretroviral regimens (100-200 mg). 1 The protocol was designed as a mechanistic investigation, however, specifically to provide insights into ritonavir's reduction of methadone plasma concentrations, first reported when higher ritonavir doses were used clinically. Nonetheless, increased methadone clearance 21 did occur after only 3 d of twice daily 200-300 mg of ritonavir, as has also been observed after longer periods at lower (100 mg twice daily) doses. 47 Thus the present investigation is of both mechanistic and clinical relevance. Second, ritonavir effects were evaluated in healthy volunteers rather than in HIV-infected patients. This was deliberate, because standard antiretroviral therapy involves several drugs, thereby precluding a careful mechanistic evaluation and attribution of results to any one specific drug.
In summary, acute and steady-state ritonavir inhibited >90% of first-pass CYP3A4/5 activity, and steady-state ritonavir inhibited >70% of hepatic CYP3A4/5 activity. Acute ritonavir inhibited apparent gastrointestinal P-gp activity, and steadystate ritonavir caused mild apparent induction of P-gp relative to acute ritonavir, although net inhibition still predominated. Ritonavir inhibits both intestinal and hepatic CYP3A and drug transport. ALF miosis was an excellent noninvasive probe for determining CYP3A4/5 inhibition by ritonavir.
articles METhoDS Clinical protocol. The investigation was approved by the University of Washington Institutional Review Board, and each subject provided written informed consent. The study population was normal healthy volunteers. Eligibility criteria included (i) age 18-40 years and (ii) within 25% of ideal body weight (body mass index <30). Exclusion criteria were (i) major medical problems, (ii) a history of hepatic or renal disease, (iii) family history of type 2 diabetes, (iv) use of medications or nonprescription preparations known to alter CYP3A activity, (v) a known history of addiction to drugs or alcohol, and (vi) access to and routine handling of addicting drugs in the regular course of employment. Women taking hormonal contraceptives were also excluded from enrollment. Both smokers and nonsmokers were enrolled. The subjects underwent a screening visit during which blood samples for fasting glucose concentration and HIV serologic status were obtained. Subjects were excluded if their glucose levels exceeded 110 mg/dl (because ritonavir can cause glucose intolerance), or if they were HIV seropositive (since monotherapy can cause HIV drug resistance). The final study population was 12 healthy subjects (6 men and 6 women; mean age 25 ± 5 years, range 19-34 years; mean body weight 74 ± 13 kg, range 55-99 kg). All subjects were genotyped for CYP3A5 at the conclusion of the study. However, since this does not affect ALF clearance, 25 enrollment was not affected by CYP3A5 genotype and it was not considered in the data analysis.
The protocol used a three-session sequential crossover design (with the control session first, due to logistical considerations). Each subject served as his or her own control. The study protocol is shown in Figure 1 . The subjects were instructed to consume no food or beverages containing grapefruit, apples, or oranges for 7 d before any study day; no alcohol or caffeine for 1 d before each study session and on the study days; and no food or water after midnight before each study session. For each session, a catheter was placed in an arm vein for blood sampling, and (if needed) a second catheter was placed for drug administration. The subjects (supine) were monitored with a pulse oximeter and automated blood pressure cuff, and they received supplemental oxygen if their saturation levels fell to <94%.
Hepatic CYP3A activity was evaluated using IV ALF as an in vivo probe, as described previously. 24, 25, 28, 48 The subjects received ondansetron (4 mg IV) for antinausea prophylaxis, followed 30 min later by ALF bolus (15 and 5 μg/kg at the control and ritonavir sessions, respectively). The subjects received a standard breakfast 4 h after ALF and free access to food and water thereafter. Venous blood was sampled for 24 h after the ALF dosing, and plasma was stored at −20 °C for later analysis. Coincident with blood sampling, dark-adapted pupil diameter was measured using a Pupilscan Model 12A infrared pupillometer with 0.1 mm resolution (Keeler Instruments, Broomall, PA) as described previously. 24, 25 Each recorded value was the mean of triplicate measurements, which typically agreed to within 0.1-0.3 mm. First-pass CYP3A activity and intestinal P-gp (and other transporters) activity were evaluated using oral ALF and fexofenadine as in vivo probes, as described previously. 24, 25, 28 The subjects received ondansetron (4 mg IV) for antinausea prophylaxis, followed 30 min later by oral ALF (43 and 4.3 μg/kg at control and ritonavir sessions, respectively) with 100 cc water. Fexofenadine (60 mg) was administered with 100 cc water 1 h after ALF. The subjects received a standard breakfast and lunch 3 and 6 h, respectively, after ALF. Venous blood was sampled for 48 h after ALF dosing, and dark-adapted pupil diameter was measured coincident with blood sampling. The protocol for methadone administration is described in an accompanying article in this issue. 21 Hepatic and first-pass CYP3A, intestinal transporter activity, and methadone disposition were assessed at baseline. The subjects then began taking ritonavir, 200 mg three times daily for 1 d, 300 mg twice daily for 6 d, then 400 mg twice daily for 2 weeks. 17, 18, 49 Initial reports of reduced methadone plasma concentrations and withdrawal occurred with ritonavir 400 mg twice daily; 3 hence this was the final target dose chosen for this investigation. A ritonavir dose-escalation lead-in is clinically standard, and 1-2 d of a lead-in dose were shown to inhibit CYP3A activity. 18 First-pass CYP3A and transporter activities and methadone disposition were determined on the second and third days of low-dose ritonavir, when CYP3A inhibition was expected. Hepatic and first-pass CYP3A, intestinal transporter activity, and methadone disposition were again assessed at steady-state ritonavir. Previous reports suggested a potential for CYP3A induction during steady-state ritonavir. 18, 19 Since the time course of potential CYP3A induction by ritonavir was unknown, and the time to evaluate hepatic CYP3A, first-pass CYP3A, and P-gp activities was potentially insufficient before commencement of induction, only first-pass CYP3A and P-gp activities were evaluated in the acute ritonavir phase. First-pass is a greater determinant than hepatic metabolism of oral drug disposition and hence the more important parameter to evaluate.
Ritonavir was administered at 7 am, 3 pm, and 10 pm on the first day, and at 7 am and 7 pm thereafter. Dosing was adjusted on study days to preclude an acute inhibitor effect from the morning dose. The subjects received their morning dose at lunch and took their evening dose at 11 pm.
The sample size was determined using a simplified analysis (paired t-test) for comparing the primary outcome variable, methadone systemic clearance. A previous study found 22 and 33% interday/intrasubject variability in IV and oral methadone clearances, respectively. 50 To detect a 30% change in clearance (using a paired t-test, with 33% variability, β = 0.8, and α = 0.05) would require 12 subjects.
Analytical methods. Plasma ALF and fexofenadine concentrations were simultaneously quantified using solid-phase extraction and electrospray liquid chromatography-mass spectrometry as described previously. 28 Data analysis. ALF plasma data were analyzed by noncompartmental methods as described previously. 24, 25 Systemic clearance of IV ALF (CL IV ) = dose IV /AUC IV , and apparent oral clearance of ALF was (CL/F) = dose oral /AUC oral . Bioavailability was (F oral ) = (AUC oral /dose oral ) × (dose IV / AUC IV ); the volume of distribution based on the terminal phase was (V z ) = dose/(AUC × λ), where λ is the terminal elimination rate constant; and the steady-state volume of distribution was (V ss ) = CL × mean residence time. ALF effect (miosis) vs. time curves were treated analogously with conventional plasma concentration curves, with similar noncompartmental analysis, to yield effect parameters similar to conventional pharmacokinetic parameters. 24, 25 Hence, the area under the effect curve (AUEC) was obtained. ALF miosis was treated similarly to plasma concentration to obtain an effect clearance (CL miosis , dose/AUEC), analogous to plasma clearance (dose/AUC). Effect clearance and dose-adjusted AUEC were used when subjects received different ALF doses. 24, 25 Statistical analysis. One-way repeated measures analysis of variance followed by the Student-Newman-Keuls test for multiple comparisons, or paired t-tests, were used as appropriate to assess the significance of differences between groups for pharmacokinetic and effect parameters (SigmaStat 3.5; Systat, San Jose, CA). Non-normal data were log transformed for analysis but reported as nontransformed results. Statistical significance was assigned at P < 0.05. The results are reported as the arithmetic mean ± SD. Plasma AUC and urine data were also expressed as ratios (ritonavir/control) and as geometric mean and 90% confidence interval of the geometric mean. Confidence intervals excluding 1.0 were considered statistically significant.
